Riemser expands its management team

  • René Just appointed CFO
  • Head of Marketing Beate Küter named COO
  • Dr Rainer Wulf joins Advisory Board

Berlin, 10. October 2018 – Riemser Pharma GmbH (Riemser), a speciality pharmaceutical company operating throughout Europe, has appointed René Just (51) as Chief Financial Officer (CFO) with effect from 1 October. This follows the appointment of former Head of Marketing Beate Küter (51) to the newly created role of Chief Operating Officer (COO) in September. The pair join CEO Konstantin von Alvensleben in an expanded three-person management team. The company also announced that marketing and sales expert Dr Rainer Wulf (68) has joined its Advisory Board.

René Just succeeds Dr Uwe Salzer, who left the company on 31 August 2018, in the role of CFO. Mr Just has over 20 years’ international experience as CEO and CFO of publicly listed companies and undertakings held by private equity companies as well as extensive M&A experience. With this expertise he will play a key role in carrying forward the internationalisation of Riemser through acquisitions and in-licensing and managing this growth efficiently and profitably. René Just was previously Group CFO for the Losberger De Boer Group. He holds a master’s degree in economics from Aarhus Universitet.

Beate Küter has been with Riemser since 2017, initially as Head of Oncology and then as Head of Marketing and Sales. Her appointment as COO recognises the central role of this function in Riemser’s business model as well as Küter’s contribution to the company’s successful development. She also worked in marketing during her time with pharmaceutical company Dolorgiet, where she worked from 1998 to 2017 and was Head of Marketing and Sales from 2012. Beate Küter began her career with the pharmaceutical and chemical company Rhône-Poulenc Rorer, where she worked from 1992 to 1998. She holds a master’s degree in economics from the Moscow Economic and Statistical Institute.

Riemser has also strengthened the expertise of its Advisory Board with the appointment of new member Dr Rainer Wulf. Dr Wulf has worked for pharmaceutical companies of varying sizes since 1982, including Sanofi, BASF subsidiary Knoll, Grünenthal and most recently Stada, where he was Director of Business Development Special Projects until 2015. Since then he has worked as a consultant in the pharmaceutical industry and the investment sector. As a member of the Riemser Advisory Board, he will in particular contribute his marketing and sales expertise to business development.

Konstantin von Alvensleben, CEO of Riemser, said: “These new additions reflect the positive development that Riemser has enjoyed over recent years and set a course for further successful growth and expansion into new global markets. René Just’s international experience and M&A expertise will be crucial in relation to acquisitions of companies and pharmaceutical portfolios. By strengthening Ms Küter’s role we are shortening decision-making channels still further. As a management team we are more strongly positioned than ever before. I look forward to working in this new structure and also to working with Rainer Wulf, whose industry experience and network will make him a valuable support for the organisation.”

 

About Riemser Pharma GmbH

Riemser Pharma GmbH was established in 1992 and emerged from the Friedrich Löffler Institute on Riems Island (Greifswald). Riemser has been in business for more than 25 years, during which it has evolved from a manufacturer of veterinary medicines to a successful provider of specialty pharmaceuticals for therapeutic niches in the field of human medicine.

Riemser sells, licenses, markets and distributes pharmaceutical products. Over 400 approvals worldwide, of which 28 took place in the last three years, are a testament to the special expertise of Riemser for the approval and opening of new markets for pharmaceutical products.

The product range especially covers prescription drugs to treat serious diseases in the therapeutic areas of oncology, infectiology, neurology, in the cardiovascular field, in dermatology, rheumatology, tuberculosis treatment, for the treatment of obesity and primary axillary hyperhidrosis. Medicinal products and food supplements complement the portfolio.

Besides its international group headquarters in Berlin, the company has three locations in Germany. In 2014 and 2015 Riemser acquired the subsidiaries Keocyt based in France and Intrapharm based in England. In addition, it has established an international distribution network. Riemser is a portfolio company of Ardian, one of the world’s leading private investment companies.

For more information, please visit www.riemser.com.

 

Press Contact

 

Charles Barker Corporate Communications

 

Jan P. Sefrin

jan.sefrin[at]charlesbarker[dot]de

Tel: +49 69 79409026

 

Tobias Eberle

tobias.eberle[at]charlesbarker[dot]de

Tel: +49 69 79409024